Compound Catalog

Synthetic pentadecapeptide studied for tissue repair, gut lining integrity, and nerve regeneration in preclinical models.

Synthetic analog of Thymosin Beta-4 investigated for angiogenesis, cellular migration, and wound healing in research settings.

Selective growth hormone secretagogue studied for GH release with minimal impact on cortisol or prolactin in preclinical models.

Melanocortin receptor agonist studied for its role in sexual arousal and CNS-mediated pathways in preclinical research.

Dual GIP and GLP-1 receptor agonist studied for superior metabolic regulation, glucose homeostasis, and body weight reduction in preclinical models.

Triple GIP, GLP-1, and glucagon receptor agonist studied for advanced metabolic regulation and weight reduction in research settings.

Mitochondria-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise mimetic effects in preclinical models.

Essential coenzyme studied for cellular energy metabolism, DNA repair, sirtuin activation, and aging biology in research settings.

Proprietary research blend studied for cortisol modulation, stress response pathways, and HPA axis regulation in preclinical models.

Copper-binding tripeptide studied for wound healing, collagen synthesis, anti-inflammatory effects, and tissue remodeling in preclinical research.

Synthetic tetrapeptide studied for telomerase activation, telomere elongation, and aging biology in preclinical and early clinical research.

Essential cobalamin coenzyme studied for neurological function, methylation cycle support, and hematopoiesis in research models.

Proprietary multi-peptide research blend combining growth hormone, tissue repair, and metabolic compounds for comprehensive preclinical research applications.

Proprietary metabolic research blend combining GLP-1 agonists and lipolytic peptides for advanced metabolic pathway investigation in preclinical models.

Master cellular antioxidant tripeptide studied for oxidative stress modulation, detoxification pathways, and immune function in research models.

Essential cofactor studied for mitochondrial fatty acid transport, beta-oxidation, and energy metabolism in preclinical research models.

Proprietary tissue repair research blend combining BPC-157, TB-500, and complementary peptides for advanced wound healing and regeneration research.

Synthetic tuftsin analog studied for anxiolytic effects, BDNF modulation, and GABAergic pathway research in preclinical neurological models.

Synthetic ACTH analog studied for neuroprotection, BDNF upregulation, cognitive enhancement, and stroke recovery in preclinical neurological research.

Synthetic melanocortin analog studied for melanogenesis, photoprotection, and MC1R pathway research in preclinical models.

Proprietary research blend studied for collagen synthesis, skin barrier function, and dermal repair pathways in preclinical models.

Stabilized GHRH analog studied for GH secretion, visceral adipose reduction, and IGF-1 elevation in preclinical and clinical research models.

Synthetic GHRH(1-29) fragment studied for pituitary GH secretion, IGF-1 modulation, and growth hormone axis research in preclinical models.

Long-acting amylin receptor agonist studied for appetite suppression, gastric emptying delay, and complementary GLP-1 pathway modulation in metabolic research.

Synergistic blend of CJC-1295 (No DAC) and Ipamorelin studied for amplified pulsatile GH release via dual GHRH and ghrelin receptor pathway activation.

Mitochondria-targeted tetrapeptide studied for cardiolipin binding, mitochondrial membrane protection, and oxidative stress reduction in preclinical models.

Non-hematopoietic erythropoietin analog studied for neuroprotection, anti-inflammatory signaling, and tissue repair via innate repair receptor activation.

C-terminal α-MSH tripeptide studied for potent anti-inflammatory effects, gut barrier protection, and melanocortin receptor-independent signaling in preclinical models.

Synthetic hexapeptide GHS-R agonist studied for potent GH secretion, appetite stimulation via ghrelin pathway activation, and GH axis research in preclinical models.

Small-molecule NNMT inhibitor studied for adipogenesis suppression, NAD+ precursor availability, and metabolic reprogramming in preclinical obesity and metabolic research.

Thymic peptide bioregulator studied for immune system restoration, T-cell function, and thymic involution reversal in aging and immunology research.

Endogenous GPR54 agonist studied for GnRH pulse regulation, LH/FSH secretion, reproductive axis activation, and hypothalamic-pituitary-gonadal axis research.

Neuropeptide studied for sleep regulation, stress response modulation, and neuroendocrine activity in preclinical models.

Sterile water containing 0.9% benzyl alcohol used for reconstitution of lyophilized research peptides and compounds.

GLP-1 receptor agonist studied in metabolic regulation, appetite signaling, and glucose homeostasis research.

GHRH analog with extended half-life studied for sustained growth hormone release and IGF-1 elevation in research contexts.